[14C]-4-N-tert-butoxycarbonylaminobutyric acid | 1021521-02-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [14C]-4-N-tert-butoxycarbonylaminobutyric acid
• CAS: 1021521-02-7
• 化学式: C₉H₁₇NO₄
• 分子量: 205.227
• InChiKey: HIDJWBGOQFTDLU-ZQBYOMGUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.38
• 重原子数：
  14.0
• 可旋转键数：
  4.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  75.63
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  [14C]-4-N-tert-butoxycarbonylaminobutyric acid 、 奋乃静 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethyl 4-((tert-butoxycarbonyl)amino)butanoate-4-14C
  参考文献：
  名称：

  A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects

  摘要：

  The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

  DOI：

  10.1021/jm7012453
• 作为产物：
  描述：

  [14C]-4-aminobutyric acid 、 2-(叔丁氧羰基氧亚氨基)-2-苯乙腈 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 以219.4 mg的产率得到[14C]-4-N-tert-butoxycarbonylaminobutyric acid
  参考文献：
  名称：

  A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects

  摘要：

  The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels. Efficacy was evaluated in the D-amphetamine-induced hyperactivity model, where perphenazine abolished hyperactivity and induced sedation and catalepsy, whereas 3 reduced hyperactivity without sedation or catalepsy. Thus, 3 (BL-1020) constitutes a prototype of novel antipsychotics possessing GABAergic activity. A phase II study is in progress.

  DOI：

  10.1021/jm7012453